After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop making copies.

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said that it will soon stop selling some compound weight-loss drugs.

Hims & Hers Health shares tumbled despite the telehealth provider beating fourth-quarter expectations and offering better-than-expected revenue forecasts for the first quarter and 2025.For the full year 2025,

Hims & Hers (HIMS) stock tumbled 20% post-market after the company released its Q4 earnings report and 2025 guidance amid a possible FDA crackdown on its GLP-1 weight-loss drugs.

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer in shortage.